期刊文献+

基础血浆B型利钠肽水平对心力衰竭患者应用重组人B型利钠肽短期临床疗效的预测价值 被引量:11

Predictive values of baseline plasma B-type natriuretic peptide levels for short-term clinical efficacy of recombinant human brain natriuretic peptide in heart failure patients
暂未订购
导出
摘要 目的评价基础血浆B型利钠肽(BNP)水平对心力衰竭患者应用重组人B型利钠肽(rhBNP)短期临床疗效的预测价值。方法选取2012年12月至2013年12月在河北医科大学第二医院心内科住院的心力衰竭患者共46例,其中男性24例,女性22例,入院后在常规抗心力衰竭治疗基础上加用rhBNP,分别计量静脉应用rhBNP前24 h、后第1、2和3个24 h液体出入量,计算每日净出量,分别将用药后每日净出量减去用药前净出量计为患者应用rhBNP后连续3个24 h的利尿效果,结合患者用药后整体临床状况改善程度评估rhBNP的短期临床疗效。基础血浆BNP值于应用rhBNP之前测定,依据其四分位数进行分组,比较血浆BNP不同水平组间rhBNP利尿效果及整体临床状况改善程度。采用双变量相关分析评价rhBNP利尿效果与基础血浆BNP水平之间的相关性。结果所有患者基础血浆BNP值380~5 000 pg/ml[1 225 pg/ml(1 689 pg/ml)]。依据基础血浆BNP水平四分位数进行分组,基础血浆BNP不同水平组间应用rhBNP后第1个24 h的利尿效果差异有统计学意义(F=3.132,P=0.035)。应用rhBNP泵点后第1个24 h利尿效果与基础血浆BNP值呈负相关(r=-0.412,P<0.01);第2个24 h利尿效果与基础血浆BNP值呈负相关趋势(r=-0.059,P=0.69);第3个24 h利尿效果与基础血浆BNP值呈负相关(r=-0.292,P=0.049)。基础血浆BNP不同水平组间患者整体临床情况改善程度差异有统计学意义(χ2=18.815,P=0.03)。结论基础血浆BNP水平高的心力衰竭患者较BNP水平低的患者应用rhBNP的短期临床效果欠佳;心力衰竭患者应用rhBNP的短期利尿效果与基础血浆BNP水平呈负相关;基础血浆BNP水平对心力衰竭患者应用rhBNP的短期治疗效果具有一定预测价值。 Objective To evaluate the predictive values of baseline plasma B-type natriuretic peptide( BNP) levels for short-term clinical efficacy of recombinant human brain natriuretic peptide( rh BNP)in patients with heart failure. Methods A total of 46 heart failure patients including 24 males and 22 females were selected between December 2012 and December 2013. For these patients rh BNP was used subsequent to appropriate conventional therapies for heart failure. 24 hours fluid input and output were recorded before and the first,second,third 24 hours after drug used. The difference value of 24-hour output day 1,day 2,day 3 after rh BNP and 24-hour output before rh BNP was defined as primary endpoint. The degree of improvement in overall clinical condition was also recorded after drug used. Baseline plasma concentrations of BNP were measured before rh BNP administration. According to the plasma BNP quartile to compare diuretic effect and degree of improvement in overall clinical status. Bivariate correlation was used to analyze the relationship between baseline BNP levels and the diuretic effect. Results The baseline BNP concentrations ranged from 380 pg/ml to 5 000 pg/ml,with a median of 1 225 pg/ml. According to the plasma BNP quartile,diuretic effect of the first 24 hours after drug administration showed a significant difference among four groups( F = 3. 132,P = 0. 035). There was a significant negative correlation between baseline BNP levels and the diuretic effect of the first 24 hours( r =-0. 412,P〈0. 01). A negative correlation trend was found between baseline BNP value and the diuretic effect of the second 24 hours( r =-0. 059,P = 0. 69). The diuretic effect of the third 24 hours and baseline plasma BNP values were negatively correlated( r =-0. 292,P = 0. 049). The degree of improvement in overall clinical status was statistically significant among the BNP groups( χ2= 18. 815,P = 0. 03). Conclusions The heart failure patients with higher BNP levels have a poor short-term clinical efficacy after rh BNP administration than the patients with lower BNP levels. The short-term diuretic effect of rh BNP is negatively correlated with baseline plasma BNP levels. Baseline BNP levels can be used to predict the short-term clinical efficacy of rh BNP in heart failure patients.
出处 《中国心血管杂志》 2017年第4期243-247,共5页 Chinese Journal of Cardiovascular Medicine
关键词 利钠肽 心力衰竭 治疗结果 Natriuretic peptide brain Heart failure Treatment outcome
  • 相关文献

参考文献5

二级参考文献50

  • 1白梅.脑钠肽在心力衰竭诊治中的研究进展[J].中国心血管病研究,2005,3(4):312-314. 被引量:23
  • 2李世强,傅向华,刘君,谷新顺,张晶,樊欣娜,姜云发,苗青.静脉注射重组人脑利钠肽对急性心肌梗死伴心力衰竭患者的急性血流动力学效应的研究[J].中华心血管病杂志,2006,34(1):23-27. 被引量:102
  • 3谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226. 被引量:228
  • 4马长生.心脏病学实践2005-新进展与临床案例[M].北京:人民卫生出版社,2005:551-556.
  • 5Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure[J]. Drugs, 2003,63 (1) : 47-70.
  • 6Boomsma F, van den Meiracker AH. Plasma A-and B-type natriuretic peptides; physiology, methodology and clinical use [J]. Cardiovase Res,2001,51(3) :442-449.
  • 7Publication Committee for the VMAC investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [J]. JAMA,2002,287(12) :1531-1540.
  • 8Colucci WS, Elkayam U, Horton DP, et at. Intravenous nesiritide, a natriuretie peptide, in the treatment of decompensated congestive heart failure[J]. N Engl J Med, 2000, 343(4) : 246-253.
  • 9Cataliotti A. Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure[J]. Circulation, 2004,109(13) : 1680- 1685.
  • 10Kemperman H, van den Berg M, Kirkels H, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device[J] Clin Chem, 2004,50 (9): 1670-1672.

共引文献336

同被引文献75

引证文献11

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部